Highlights Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
2.23 ^USD	+4.69%		-4.29%	+34.34%

15/05	Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/03	Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
North American Morning Briefing : Stocks Set for -2-	28/03	DJ
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	03/23/03	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Galectin Therapeutics Inc. Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	16/23/16	CI
Galectin Therapeutics Inc. Provides Final Randomization Status of Navigate, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	02/23/02	CI
Galectin Therapeutics Inc. Announces the End of Enrollment of Navigate, Its Seamless, Adaptive Phase 2B/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	05/23/05	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer	12/22/12	CI
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE	06/22/06	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress(TM) 2022	21/22/21	CI
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis	14/22/14	CI
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/22/31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Highlights

Filters